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Abstract 
Pneumocystis jirovecci pneumonia (PJP) in HIV/AIDS is a significant opportunistic 
infection. As CD4 counts decrease, so does specificity of chest X-ray (CXR). 
AIM: To determine the proportion of bronchoscopically proven PJP in HIV infected 
adults, CD4 counts, CXR signs and compare PJP to TB. 
 
METHODS: The proportion of bronchoscopically proven PJP and co-infection was 
determined. Sensitivity and specificity of CXR for the diagnosis of PJP and TB, and 
frequency of CXR signs were determined.  
 
RESULTS: PJP was present in 26.6% and co-infection 19%. Median CD4 (13 cell/mm
3
) 
was significantly lower for PJP patients (p = 0.0089). CXR sensitivity for PJP was 33% 
and specificity was 100%. Bilateral, multilobar and diffuse disease, bronchopneumonia, 
nodules and cavitation overlapped for PJP and TB. Unilateral and unilobar disease 
indicated TB over PJP. Effusions and lymphadenpopathy were not seen with PJP.  
 
CONCLUSION: PJP makes up a quarter of indeterminate diagnoses in HIV infected 
adults. Sensitivity of diagnosis on CXR is low. The CXR diagnosis of TB is made more 
confidently, but is overcalled. In patients with low CD4 levels, a diagnosis of PJP should 
be considered as important as TB. 
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INTRODUCTION 
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1 INTRODUCTION 
1.1 Overview 
Pneumocystis pneumonia or Pneumocystis jirovecii pneumonia (PJP) in the setting of 
Human immunodeficiency virus (HIV) and Acquired immunodeficiency syndrome (AIDS) 
is still a significant opportunistic infection worldwide, despite the advent of antiretroviral 
therapy (1,2). It typically presents in patients with low CD4 counts below 200cells/mm
3 
(2,3, 4).  Pneumocystis Pneumonia carries a high morbidity and mortality rate and its 
diagnosis is imperative for timeous and effective antimicrobial therapy
 
(1,2, 5). PJP still 
remains a common initial presenting illness in HIV infected individuals in the developed 
world in a background where a significant percentage of patients are unaware that they 
have HIV infection ( from 2001 – 2006 rates of HIV testing in the USA show only 40% of 
the population ever tested) (6)
 
. Though having decreased dramatically, opportunistic 
infections (OIs) remain one of the main causes of hospitalization and death in HIV infected 
people
 
(6). 
 
In the developing world Pneumocystis pneumonia has been thought to be an uncommon 
pulmonary opportunistic infection especially in the light of the widespread rates of 
tuberculosis (TB) and bacterial pneumonias due to HIV/AIDS (2). More recent reports are 
emerging, however, revealing PJP’s more commonplace prevalence (1). As CD4 count 
deteriorates so does the specificity of chest X-ray (CXR) findings making the diagnosis of 
specific pulmonary infection all the more difficult
 
(7). There is also overlap of radiographic 
signs within the spectrum of HIV pulmonary disease as well as coexistence of more than 
one pathogen in a single patient presenting with disease
 
(4,7). The lack of availability and 
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access to laboratory and bronchoscopic resources to confirm PJP infection is thought to 
have in part contributed to the under-reporting of Pneumocystis pneumonia in HIV/AIDS 
in Africa
 
(2). 
 
 
In reports emerging from African medical literature, CXR’s read blind by radiologists were 
over reported as TB and not as PJP, where bronchoscopy results of these patients showed 
PJP infection rather than TB
 
(8). In HIV/AIDS patients with low CD4 counts , non-specific 
CXR patterns have been  seen which have been misinterpreted as TB or a non specific 
CXR diagnosis was made (9). 
1.2 Global HIV and HIV in South Africa  
At the end of 2008, 33.4 million people worldwide were estimated to be living with 
HIV/AIDS according to UNAIDS2009
 
(10). 
.
Although the prevalence rate has levelled off, 
numbers of people living with the disease have continued to increase, as estimated AIDS- 
related deaths decrease (approximately 10% lower in 2008 than in 2004)(11). 
 
In 2008, 2.7 
million new infections occurred worldwide (30% lower than during the epidemic’s peak in 
1996) (10). Women comprise half of adults living with HIV/AIDS worldwide and young 
people under 25 yrs of age account for more than half of all new HIV infections (11). In 
contrast to 2.3 million people living with HIV/AIDS in North America and Europe 
documented for 2008, there were 4.2 million in South/South-East Asia living with 
HIV/AIDS
 
(10). 
 
There is not a homogenous AIDS epidemic but a worldwide diversity of AIDS by region 
or country. Sub-Saharan Africa accounts for only 12% of the world’s population, yet has 
the majority of people living with HIV/AIDS (22.4 million- and a 5.2% prevalence) (10). 
HIV is the leading cause of death in the region, with Southern Africa the worst affected.
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With more than 5.7 million people living with HIV/AIDS, South Africa has a prevelance 
rate of 16.9% and the world’s largest population of people with HIV infection (10). The 
first case of HIV/AIDS in South Africa was reported in 1982
 
(12).
 
The prevalence rate in 
SA is significantly higher than the overall rate in Sub-Saharan Africa and globally. Overall 
death rates in South Africa have increased by 80% - largely due to HIV/AIDS
 
(12). In 2007 
there were 350 000 AIDS deaths in South Africa and AIDS was estimated to have 
accounted for nearly half of all deaths in 2006
 
(12).  
 
The overall picture shows a change. The 1.4 million AIDS – related deaths in 2008 in Sub-
Saharan Africa, represents an 18% decline in annual HIV– related mortality since 2004 
(10). Between 2003 and 2008 access to antiretroviral drugs increased 10-fold in middle and 
low income countries. This has reduced mortality related to HIV by half in a treatment 
centre in the Western Cape between 2001 – 2005, as patients with less immunosuppression 
joined the program
 
(11).  
 
However, the South African Department of Health states that  ‘there is no evidence of a 
decline in new HIV infections, 29% of pregnant women accessing public health services 
tested HIV positive in 2008’ (10). Notably, there were also over 1 million AIDS orphans in 
South Africa by the end of 2007
 
(12). 
 
 
 
 
  
5 
 
Reflected in the epidemiology since a quarter century ago, when Pneumocystis pneumonia 
heralded the onset of the AIDS epidemic, there has been a shift in the presentation of 
HIV/AIDS with the majority of new cases occurring in the developing world (1,11,12,13). 
In the developed world, opportunistic infections are diminishing in frequency, whereas in 
other settings, where there is reduced access to antiretroviral therapy, opportunistic 
infections remain frequent
 
(11). This has led to differences in presentation of HIV-related 
pulmonary disease across the globe, notably the difference in the developed versus the 
developing world, and this will be explored in the South African context. 
1.3 Antiretroviral Therapy 
The advent of highly active anti retroviral therapy (HAART) has allowed for immune 
reconstitution with prolonged viral suppression and reductions in rates of opportunistic 
infections and AIDS as well as related reduction of mortality in Europe and North 
America(1).
 
From 1996-2004, in10 USA cities, caring for 3000 infected HIV patients per 
year, AIDS-related deaths were shown to have dropped  from 7 deaths/100 person years to 
1.3 deaths/100 person years (14).
 
This correlated directly with an increased HAART utility 
from 43% of patients in 1996 to 82% in 2004 in the same study. Immune reconstitution 
due to HAART has given rise to the improved mortality and morbidity from conditions 
such as cytomegalovirus and Kaposi’s sarcoma, where specific OI preventive measures 
have not been available
 
(15).
 
Long term use of HAART and higher CD4 cell counts are 
now associated with death from ‘non-AIDS’ illnesses such as chronic viral hepatitis, 
hypertension, cardiovascular disease, diabetes and pulmonary diseases as well as non-
AIDS malignancies similar to the general community (14). 
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Similar benefits have been seen in South Africa, Zambia, Uganda, South East Asia and 
Latin America where such programs are delivering antiretroviral therapy
 
(10). Overall 2, 
120 000 people received HAART in Sub-Saharan Africa as of December 2007. This means 
that 70% of those in need of HAART in Sub-Saharan Africa have not yet accessed therapy. 
In South Africa itself 460 000 people living with HIV/AIDS (approximately 10% of the 
HIV population) were receiving HAART by end of 2007 (1,11,12 ).  According to 
UNAIDS 2009, South Africa now has implemented the largest antiretroviral therapy 
program in the world to reduce mortality from HIV disease and related infections
 
(11). 
There are suspected high numbers of people living with HIV and not taking ARV’s. This is 
most likely due to a combination of factors, including lack of information about ARV’s, 
lack of knowledge of personal HIV status, diminished societal awareness of HIV and its 
processes of transmission (although recent improvements to this have been made), and/ or 
non-compliance with ARV medication. This correlates with data reported in 2008 from 
ante-natal clinics in Johannesburg where the mean baseline CD4 count was 154 cells/mm
3
 
which indicates  advanced disease (12, 16). Similar findings were reported in 2009, with a 
mean CD4 count at first time presentation at an urban HIV clinic in Soweto of 
109cells/mm
3
 in the female population
 
(17). Undetected and later presentation of 
HIV/AIDS,  as well as non- accessed HAART, contribute to the particular disease pattern 
and frequency of opportunistic infections seen in South Africa and sub-Saharan Africa.  
  
7 
 
1.4 Opportunistic infections in HIV/AIDS 
1.4.1 Epidemiology of Opportunistic infections  
In the USA and developed world, the incidence of opportunistic infections (OI) has 
decreased definitively from 1992. This is probably due to the introduction of combination 
antiretroviral therapy as it has become simpler, more effective and less toxic (1,6,15).
 
 
The high mortality in HIV infected patients in Sub Saharan Africa relates to the low CD4 
counts at presentation (13). A high early mortality of between 8-26% of patients within the 
first year of starting antiretrovirals is found in patients with baseline CD4 counts of 
50cells/mm
3
 and less
 
(2). OI’s are the major cause of mortality in these patients (1). HIV 
has fuelled the TB epidemic that has expanded globally, and its incidence is several 
hundred times greater in the AIDS population than the general population (3). In 2006, 9.2 
million new cases of TB occurred worldwide. Over a third of these cases were in Africa 
and 38% of the 1.7 million worldwide deaths occurring from TB in this period were 
accounted for by the World Health Organzation (WHO) for the Africa Region. Thirteen 
out of 15 countries with the highest incidence of TB were from Africa (1).
 
Despite the 
availability of HAART ‘Pneumocystis pneumonia remains a leading cause of morbidity 
and mortality’ (18) and bacterial and other fungal opportunistic infections continue to 
remain commonplace
 
(7). 
 
1.4.2 Pulmonary manifestations of HIV/AIDS  
In a review of thoracic AIDS in 2002, pulmonary manifestations of HIV disease were 
common and accounted for 30-40% of acute admissions to a London hospital (3).
 
In the 
developed world the commoner OI’s cited for discussion in patients with AIDS in the era 
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 of HAART included bacterial pneumonias, Pneumocystis pneumonia, Mycobacterium 
tuberculosis, Cryptoccoal neoformans infection, Mycobacterium avium complex (MAC) 
and cytomegalovirus (CMV). All are seen with higher frequency in HIV positive patients 
and are seen with increased frequency as CD4 counts drop below 200cells/mm.
3
The 
increasing risk for all pneumonias is associated with decreasing CD4 counts,
 
and clinically 
apparent recurrent bacterial pneumonias continue to be the commonest, occurring before 
and after the onset of AIDS
 
(3).
 
TB remains the commonest opportunistic pneumonia in  
sub- Saharan Africa while bacterial pneumonia is the most frequent opportunistic 
pneumonia in the United States and Western Europe (19). Pneumocystis pneumonia is the 
commonest AIDS-related OI in the United States, and together with TB, is the commonest 
OI in Western Europe, now
 
in the HAART era (19).
 
The overall incidence of PJP due to 
ART and PJP prophylaxis is on the decline in the United States. 
PJP has been increasingly reported in sub-Saharan Africa where it had been previously 
thought to be a rare pathogen. TB remains the dominant OI in Africa and in low and 
middle income countries (19). In both settings, PJP remains a ‘persistent and deadly 
opportunistic infection’ (20).  
 
1.4.3 PJP as a Pulmonary Opportunistic Infection in HIV/AIDS 
 Despite availability of HAART, Pneumocystis pneumonia continues to cause significant 
morbidity and mortality in HIV- infected populations. It occurs in patients unaware that 
they have HIV, who are not on ARV’s and present with OI as the initial presentation of 
late HIV disease
 
(18). Poor adherence to HAART, economic, psychosocial, biological 
factors and unexplained resistance, all prevent efficacy of ARV’s (6). Rates of HIV testing 
in the USA in a 2001-2006 survey indicate that only 40% of surveyed adults aged 18-64 
had ever been tested
 
(6). This could explain, in part, the presentation of as many as 25-50% 
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of HIV patients with CD4<200cells/mm
3 
at first diagnosis, at both rural and inner urban 
HIV clinics within the USA
 
(6). In the Developed world, PJP is still the initial presentation 
of HIV in the HAART era, in 37% of patient compared to 39.3% in the pre HAART period 
1990-1995. This was shown in a multicentre study done in the USA, and PJP was 
associated
 
with a high mortality rate (37% in the HAART period and 45% in the pre- 
HAART era ). In the same review, only a third of patients received PJP prophylaxis at any 
one time, and mortality was found to be higher in patients not taking prophylaxis
 
(20). 
 
1.5 The CXR in pulmonary infections in HIV/AIDS 
1.5.1 Relevance of the CXR  
A plain CXR together with a clinical assessment remains the starting point and mainstay 
investigation of opportunistic chest infections, in conjunction with the patient’s CD4 count. 
These, together, act as diagnostic guidelines. Computed Tomography (CT) is usually not 
required except as a problem solving tool (3). Despite the diagnostic indicators of 
radiographic patterns, CD4 counts, and clinical symptomatology, considerable overlap and 
atypical radiological presentation is encountered (3, 7 ). This is confounded by a 
differential diagnosis which also includes non infectious HIV/AIDS pathology (3). 
Imaging on CXR is usually sought, but radiographic patterns on CXR in 
immunocompromised patients are often nonspecific
 
(4). Indeed, as CD4 levels drop below 
200 cells/mm
3 
, non specificity of CXR patterns increases
 
(3,4,7). Added to this, it is well 
documented that a normal CXR does not imply absence of disease in significantly 
immunocompromised patients, belying the presence of PJP
 
and active TB in 10% and up to 
20% of patients respectively (7 ,21). Greenberg et al have shown that clinical evaluation 
was also not a reliable indicator of disease. In patients who were both HIV infected and TB 
culture positive, there were between 50-70% false negative tuberculin skin tests and up to 
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50% negative acid fast bacilli in sputum or bronchoalveolar lavage (BAL). In these 
patients, the findings of cough, abnormal CXR, haemoptysis and elevated white cell counts 
prompted investigation
 
(21). 
1.5.2 Diagnostic Patterns on CXR  
Interpretation of radiographic patterns on CXR narrows the possibilities of potential 
pathogens. CXR can, however, be non-specific and variable, so the importance of a CD4 
count together with symptoms of hypoxia, environmental exposure, HAART / OI 
prophylaxis and the demographics of the disease are well recognized contributors to 
diagnosis
 
(1,4,7). 
 
In patients with CD4 > 200cells/mm
3
,
 
bacterial pneumonias caused by S pneumoniae, H 
influenza, S. aureus and Pseudomonas aeruginosa occur, and patients are more likely to 
acquire invasive pneumoccocal disease
 
(1,3,4)
 
.
 
Studies originating in South Africa 
(miners) and from Kenya showed that the risk of acquiring pneumonia is clearly associated 
with decreasing CD4 counts
 
(1). The USA and Europe have experienced a reduction in 
rates of bacterial pneumonia after the introduction of HAART (1,3, 15 ).
 
Lobar and 
segmental consolidation,  effusions  and the rapid progression of bacterial pneumonias in 
HIV positive patients give rise to cavitation and atypical infiltrates. This makes 
differentiation of bacterial pneumonia from TB and PJP difficult (3).TB presents with 
more typical radiographic patterns of reactivation cavitation, bronchiectasis  and  
bronchovascular distortion in patients with CD4>200/mm
3
  (3,4,7,21). 
 
With CD4 100 – 200 cells/mm3 bacterial pneumonia, primary TB, PJP and fungal 
infections are encountered, radiological indicators of disease pathogens become less 
distinct as lobar consolidation and effusion may be manifestations of both primary TB and 
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bacterial pneumonia
 
(1,3,7). Visible lymphadenopathy on CXR is more suggestive of TB 
(Figure 1.1) (4) 
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Figure 1.1 Primary TB 
Frontal CXR in a 31 yr old female demonstrating right hilar and paratracheal nodes , right 
middle lobe consolidation and veiling of the right base due to a pleural effusion in a patient 
with primary TB.  
  
13 
 
PJP presents typically with diffuse bilateral and perihilar groundglass opacities and thin 
walled cysts (figure 1.2).The complications of peumothorax/pneumomediastinum may be 
seen without adenopathy or effusions (1,4). However, multifocal airspace shadowing, 
thickened reticular and linear infiltrates, mass lesions, nodules, cavitations and even 
adenopathy are atypical manifestations of PJP
 
(Figures 1.3, 1.4 and 1.5). The possibility of 
a normal CXR and non-specific CXR patterns in PJP disease makes  clinical features such 
as  hypoxia and laboratory features such as CD4<200cells/mm
3 
important diagnostically. 
Acute rate of onset of disease might help point to bacterial pneumonia, oedema or 
pulmonary haemorrhage, whereas a subacute process over days or weeks are usually 
viruses , PJP, TB or fungi (7). 
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Figure 1.2 Typical PJP 
Frontal CXR of a 34yr old male with typical features of PJP demonstrating hazy 
groundglass  opacification and fine reticulation  bilaterally. 
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Figure 1.3 Atypical PJP, coarse reticular pattern 
Frontal CXR in a 34 yr old female demonstrating atypical PJP with a bilateral diffuse 
coarse reticular pattern with left upper lobe and lower lobe segmental consolidation. 
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Figure 1.4 Atypical PJP, nodules and consolidation 
 Frontal CXR in a 32 yr old male demonstrating atypical PJP with bilateral patchy 
consolidation, coarse reticulation and ill defined large nodules bilaterally. 
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Figure 1.5 Atypical PJP, coarse reticular nodular pattern 
 Frontal CXR in a 35 yr old male demonstrating  atypical PJP with a coarse bilateral 
reticular pattern, large nodules and multifocal airspace shadowing.  
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Acute and chronic bacterial pneumonias can present with similar patterns including 
cavitatory lung nodules (Figure 1.6) (4,7 ) . Multiple lung nodules and diffuse reticulation 
can represent fungal disease (cryptoccocal , histoplasmosis in endemic areas),TB and 
septic emboli.  
 
 
Figure 1.6 Bacterial pneumonia 
Frontal CXR in a 40 yr old male demonstrating  necrotising Klebsiella pneumonia 
involving the right upper lobe and left lower lobe especially at its apex. 
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Patients with CD4 <100cells/mm
3 
present with bacterial pneumonias, atypical appearances 
of  TB, PJP, Mycobacterium Avium Complex (MAC), Cytomegalovirus (CMV) and fungal 
infections. At depleted CD4 counts (typically <100cells/m
3 
)
 
the commonest pulmonary 
fungal infection in patients with AIDS is cryptococcal pneumonia. It may also be 
associated with meningitis and demonstrates diffuse reticular/nodular patterns resembling 
PJP on CXR. Multifocal consolidation and nodules that tend to cavitate also occur with 
this pathogen
 
(3, 7). Miliary and endobronchial TB give rise to non specific diffuse 
bilateral parenchymal patterns, while MAC encountered with CD4 < 50cellsmm
 
will 
demonstrate nodules combined with airspace shadowing and cavitating opacities that can 
mimic TB
 
(4).
 
CMV encountered at CD4 <100cells/mm
3 
shows perihilar and varied lower 
zone non-specific infiltrates often attributed to PJP (Figure 1.7)
 
(3). This highlights the 
large degree to which CXR findings in patients with low CD4 counts overlap (Figure 1.8A 
and B). 
 
In patients with AIDS, therefore, one or more of the differing patterns seen on CXR could 
be due to a number of causative organsms .These include PJP, TB,MAC, cryptocccal 
pneumonia, Aspergillus, and CMV. A normal CXR does not exclude active disease in 
severely immunocompromised patients who are unable to mount a significant 
inflammatory response. Non infectious AIDS related diseases such as Kaposi’s sarcoma, 
lymphocytic interstitial pneumonitis (LIP)
 
, non specific pneumonitis and lymphoma may 
all give rise to the above patterns requiring them to be included in the differential diagnosis 
(1, 3). 
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Figure 1.7 PJP and CMV 
Frontal CXR in a 43 yr old woman with both PJP and CMV infections. A diffuse ground 
glass, bilateral reticular nodular pattern is present, with cavitation in the left apex. 
 
Fig 1.8A below is of a frontal CXR in a 29 yr old female demonstrating atypical PJP with 
right lower lobe consolidation and a coarse bilateral reticular pattern.This is shown 
alongside  Fig 1.8B of TB for comparison.The CXR features of atypical PJP are non 
specific and  indistinguishable from those of TB.  
21 
 
 
A 
 
B    
Figure 1.8 Atypical PJP compared to TB 
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1.6 Pneumocystis Pneumonia 
1.6.1 PJP in the Developed World 
1.6.1.1 PJP detection in the Laboratory 
Pneumocystis carinni was identified in 1909 as a protozoan and was found to be the 
causative agent for Pneumocystis pneumonia. It was reclassified as a fungus in 1988, and 
the infecting and host specific agent in human beings was also renamed as Pneumocystis 
jirovecii (PJP) (4,22). PJP has unique tropism for the lung, only invading and causing 
disseminated disease in cases of severe immunosuppression. Person-to-person 
transmission, rather than reactivation of latent infection when the immune system fails, is 
thought to be the mode of infection (22).The organism is identified by immunoflourescent 
staining of both its trophic and cystic forms, in sputum and BAL fluid. Earlier stains were 
only able to pick up either form of the pneumocystis , trophic or cystic, rather than both 
(22). In the absence of pneumonia, pneumocystis organsms are rarely detected by 
commonly employed staining methods. When cysts are visualised microscopically 
however, then active pulmonary disease is likely
 
(23). 
 
Even more sensitive is newer nested polymerase chain reaction (PCR) detection of DNA of 
PJP in asymptomatic individuals who do not demonstrate pulmonary disease and who may 
act as a reservoir of PJP disease. This may be a clinically unrecognized element in 
transmission
 
(24).  
1.6.1.2  Clinical History of PJP infection 
The first cases of PJP were described in premature infants and malnourished children in 
crowded institutions in Second World War Europe, and later seen as sporadic pneumonias 
in immunocompromsed patients with underlying malignancies, congenital defects, 
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immunosuppressive therapy and in those with renal transplant
 
(2, 25)
 . In the early 1980’s 
PJP was transformed from a rare to more common pneumonia as it heralded the AIDS-
epidemic(2). It became the AIDS-defining illness in two third of patients in the USA
 
(2).  
In the developed world, before 1996, PJP was predominantly seen in male homosexuals. 
After 1996, an increasing number of heterosexual men and women presented with PJP. In 
HIV carriers, in the post- HAART period, well over half of them never knew their HIV 
status, and the onset of PJP was the first time they had learned of their HIV status
 
(18). The 
first important decline in PJP prevalence occurred with Pneumocystis pneumonia 
prophylaxis in 1989 (25). Thereafter the emergence of HAART changed the natural history 
of HIV infection, causing a further significant decrease in opportunistic infection 
prevalence, including a decrease in OI’s for which no specific prophylaxis was available 
(2,15)
 
.
 
An incidence of PJP of 20 cases /100 person years was found in the pre-HAART 
era in patients with CD4 counts<200cells / mm
3 
compared to a rate of 0.3 cases/100 person 
years as early as 1998 due to HAART (1).
 
Immune reconstitution conferred by HAART 
has allowed discontinuation of PJP prophylaxis when CD4 counts rise above 200 cells 
/mm
3
. Similarly, with the use of HAART, AIDS- related deaths have dropped precipitously 
(15)
 
. 
 
1.6.1.3 The Significance of PJP as an Opportunistic Infection in the HAART Era 
PJP remains the most serious and major OI in HIV infected persons despite HAART and 
remains a leading factor in the morbidity and mortality of patients with HIV
 
(2, 18). 
Primary prophylaxis is instituted in patients with CD4 counts < 200 cells/mm 
3 
or in 
patients with oropharyngeal candidiasis regardless of the CD4 count. Secondary 
prophylaxis is given to patients with a history of previous PJP infection. In both instances, 
prophylaxis is continued for 3 months after the CD4 count rises above 200 cells/mm 
3 
in 
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response  to ART (19). In a recent  report, experience in a single developed world centre 
over a 21 year period, cites significant mortality rates due to PJP in the HAART - 
corticosteroid therapy period (ranging from 8,2% to 11,5%) similar to the pre-HAART , 
pre-corticosteroid period (18). Higher mortality rates of between 30% - 60% are also 
reported (26). PJP related mortality is associated with patients who have low partial 
pressures of oxygen, low haemoglobin, a second or third episode of PCP, and/or the need 
for ICU admission (18). It is the commonest cause of respiratory failure in HIV 
individuals, with a mortality of 80% in those patients requiring mechanical ventilation
 
(20). 
In one study in 2008, two- thirds of patients were not on PJP prophylaxis, despite 
indications for it, and their outcomes, because of this, were less favourable than those who 
were on prophylaxis (20). 
 
Patients presenting with PJP usually have CD4 counts below 100 cells/mm
3 
(2,15,18).
  
It is 
clear that long term HAART and immune reconstitution leads to protection from OI’s 
including PJP when CD4 counts rise above 200 cells/mm
3 
(1)
 
. The median CD4 count of 
patients in the ASD (Adult and Adolescent Spectrum of Disease) Project 2000 on HAART 
contracting PJP, was extremely low (29 cells/mm
3 
) (15)
 
and this was also found to be the 
case in a similar study conducted in Europe (CD4 counts 30 cells/mm
3 
)
 
(2). All patients 
contracting PJP,whether on HAART or not, had very low CD4 counts (50 cells/ mm
3
 and 
less)
 
(2,15). 
 
In New York City, despite declining HIV patients in hospitals overall, the percentage of 
hospitalized HIV-infected patients who have OI’s has remained stable in the HAART era. 
Non identification of HIV infections, poor adherence to HAART and PCP prophylaxis, the 
possibility of poor antimicrobial efficacy at low CD4 counts and antimicrobial resistance, 
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all contribute to the ongoing prevalence of PCP
 
(6)
 
.Consistent prescribing of HAART to 
patients with lowered CD4 counts has the most profound effect on survival and is needed 
together with adequate PJP prophylaxis , when CD4<200 cells/mm
3 
occurs
 
(18). What has 
changed in the developed world is that more cases of PJP result from failure to diagnose 
HIV infection, rather than from the inevitable progression from HIV to AIDS as was seen 
before the availability of antiretroviral therapy (18). 
 
1.6.2 PJP in Africa 
1.6.2.1 PJP Prevalence in Africa 
Low PJP prevalence rates in Africa continue to be reported in studies based on sputum 
results (27, 28, 29). More recent studies reporting high prevalence of PJP in Africa base 
their prevalence rates on bronchoscopic findings. Patients are generally referred for 
bronchoscopy because both clinical and radiological parameters are indeterminate (or even 
normal) (2, 26). At times, as in studies from Zimbabwe and Ethiopia, patients were 
included when they were smear negative for TB and unresponsive to anti-microbial 
therapy (30, 31).  
 
The prevalence of PJP in Africa varies according to different reports and PJP co- exists 
with the burden of TB and bacterial pneumonias. The latter two are reportedly the 
dominant OI’s in Africa (2). Early studies from Africa in the 1990’s cited PJP as an 
uncommon OI
 
with prevalence rates of 0-11%
 
(2, 30)
 
.
 
Reasons for this may have been 
limited diagnostic resources such as laboratory and bronchoscopy facilities. The possibility 
of actual infection being less common may also have been due to bacterial pneumonia and 
tuberculosis causing early demise of the patients before CD4 count was low enough for 
them to contract PJP
 
(2).
 
Over time, studies have emerged showing a greater prevalence of 
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PJP in African countries. Reports from 1990 to 1995 originating in Zimbabwe where 
bronchoscopy was employed for diagnosis yielded higher incidence (22%) (32) and 
prevalence (33%)(31) for PJP, and a co-infection of 9,3% where 6 patients had both PJP 
and TB. A study from Kenya in 2003 found a prevalence of 37, 2% for PJP in patients who 
underwent bronchoscopy
 
(33).  An Ethiopian study found 30,3% prevalence of PJP  (by 
sputum analysis) in 119 HIV positive patients who were smear- negative and culture 
negative for Mycobacterium tuberculosis (30). In another more recent Ethiopian 
publication, 131 smear-negative, HIV positive patients, had CXR’s assessed by two 
radiologists blinded to the clinical diagnosis. Thirty six percent of the infections mimicked 
each other on CXR, where 82% of clinical diagnoses were made up of TB, PJP and 
Bacterial pneumonias (34). Against the more recent trend of an increased prevalence of  
PJP in Africa, a study from northern Tanzania using BAL in 120 HIV infected patients 
demonstrated a 7,5% prevalence of PJP, where median CD4 count of the patients was 47 
cells/mm 
3 
( 35 ). 
 
PJP has had a significant unproven prevalence. In 1999, Mahomed et al published a 
prevalence of bronchoscopically proven  PJP in 67 HIV positive patients in Johannesburg 
teaching hospitals, of 27,3% (in African) and 58,8%  (in European) patients. Sputa were 
negative for TB and PJP. There was no statistical significant difference of PJP prevalence 
between the two HIV population groups, nor any significant difference of PJP prevalence 
between 67 HIV positive patients and 36 HIV negative renal transplant patients in this 
study
 
(36).  
 
A South African study in 2001 examined 39 HIV positive patients with dual 
Mycobacterium tuberculosis and Pneumocytis jirovecii by sputum analysis. The mean CD4 
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count of these patients was 90 cells/mm
3 
. CXR findings included patchy bilateral 
infiltrates and a reticular nodular pattern, lymphadenopathy, focal consolidation with or 
without cavitation, and pleural effusions. Dual infection for PCP and TB as described in 
this paper, is only rarely reported
 
. TB exerted the more dominant role in the morbidity of 
the disease. This was evident as patients who were treated for TB only, did better than 
those who were treated for PCP only (23).  
 
1.6.2.2. Pneumcystis Pneumonia on CXR 
Radiographically, PJP typically presents with characteristic diffuse bilateral fine reticular 
and hazy ground glass opacities in a over 80% of cases. However 10 – 15%   may present 
with a normal CXR (26). Atypical features include asymmetric and nodular opacities, 
lobular pneumonia, cavities, lymphadenopathy and effusions
 
(16, 26), Patients who are 
smear- negative for TB, and whose CXRs are either suspicious for TB or diagnostically 
non specific, are often  treated for TB. A previous lack of awareness for PJP suggests that 
PJP has been a poorly recognized differential diagnosis of TB. Furthermore, radiologists 
may not agree with each other with regard to the radiological diagnosis. An Ethiopian 
study of HIV patients which yielded 33,6% with bacterial pneumonias, 29,8% with PJP, 
23,7% with TB and 13% with double infection showed discordant results of ‘blind’ CXR 
readings by 2 radiologists which were highest for the diagnosis of TB and PJP (8). 
 
It is unclear whether lack of awareness and restriction of diagnostic resources prevented 
accurate diagnosis of PJP in Africa, or whether indeed PJP is only now emerging as a new 
and serious opportunistic pathogen in Africa
 
(2). The literature also suggests PJP has been 
incorrectly managed and treated under the ‘guise’ of smear negative TB (2, 8).  
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1.7 Study Aims 
 
This study aims to analyse the proportion of bronchoscopically proven PJP and rates of co-
infection in HIV infected adults, where the clinical and radiographic diagnosis was 
indeterminate. The study also aims to correlate the bronchoscopic diagnoses with the CD4 
counts and evaluate the radiographic features.  
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2 MATERIALS AND METHODS 
Ethics approval for this retrospective study was obtained (Appendix A). HIV positive adult 
patients with indeterminate CXR’s were collected consecutively from 1996 -2003 from the 
combined Radiological-Clinical Respiratory meeting taking place weekly at Helen Joseph 
Hospital (HJH). 
The Medicine department at the hospital offers both outpatient and inpatient services, with 
admission occurring through casualty or through the outpatient departments, including the 
large HIV Clinic. The hospital has 575 beds, which includes 335 Medical beds, comprising 
4 Medical Units. 
The Medical Units assess and refer patients to the Respiratory Unit if they have 
i) an indeterminate clinical and radiological diagnosis 
ii) complicating pathology 
iii) unresolving pathology 
iv) the need for Cardio-thoracic intervention 
v) specialised Respiratory and /or Chronic Respiratory disease eg Asmtha,  
 
2.1 Inclusion criteria 
 The following inclusion criteria applied to the study: 
i) HIV positive adults referred to the Respiratory Unit at HJH. 
ii) Inconclusive CXRs presented at the combined Radiological-Clinical Respiratory 
meetings between 1996 -2003.  
iii) Patients with an indeterminate clinical diagnosis, whether by clinical examination, 
blood results or non-contributory sputa results. 
iv) Patients who underwent bronchscopy. 
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2.2 Exclusion criteria 
The following exclusion criteria applied 
Patients whose bronchoscopic results were obtained but whose CXRs were missing. 
2.3 Data collection  
 The following data related to the patients were recorded from clinical records 
i) Age , Gender 
ii) Gender 
iii) CD4 count 
iv) Bronchoscopic result 
.  
2.4 Bronchoscopic tissue analysis 
Tissue sections were stained with Grocott ( for Pneumocystis and other fungi), alcian-blue 
(for Cryptococcus), Ziehl-Neelsen (ZN) (for Mycobacteria) in addition to haematoxylin 
and eosin. Tissue analysis was performed by the National Health Laboratory Services 
supporting the Helen Joseph Hospital (Professor Gil Murray). 
 
2.5 CXR reading 
The CXR’s were analysed by two departmental radiologists other than the author who 
were blind to the bronchoscopic results, radiological reports and clinical findings other 
than the HIV positive status of the patients. The radiological description of the pathology 
found on CXR, and the patterns identified, were documented on a Data Collection Sheet 
(Appendix B) which included the following sections: 
Location 
Distribution 
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Description 
Character: 
Complications/further signs. 
Radiological diagnosis 
2.6 Data analysis 
The proportion of PJP and TB in this group of indeterminate CXR’s was determined and 
the presence of co-infections with PJP was evaluated.  
Overall CD4 counts of all patients were assessed and CD4 counts of PJP group and of the 
TB group were analysed. 
Sensitivity and Specificity of the CXR for the diagnosis of PJP against proven 
bronchoscopic result was calculated. 
CXR features of proven PJP cases were analysed with regard to the the frequency of 
occurrence. 
CXR findings in PJP were categorised into ‘typical’ and ‘atypical’ patterns.  
According to Waite et al and Webb et al typical PJP CXR pattern was defined as diffuse, 
bilateral and perhilar, fine reticular patterns without effusions or adenopathy (4,26). 
Atypical radiographic findings of PJP were defined as focal consolidation, masses, 
cavitation and adenopathy (4, 26).  
CXR features in proven TB patients were also analysed for the frequency of occurrence.  
 PJP and TB CXR features were compared with regard to frequency of occurence. 
 Inter-reader correlation for CXR variables and diagnosis was performed. 
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2.7 Statistical analysis  
 Data was analysed using STATISTICA 9.0 statistical program. Results were expressed as 
mean and standard deviation or median [range] for age, CD4 counts, and frequencies and 
percentages for categorical variables. 
 Sensitivities and Specificities were calculated for CXR diagnosis vs Bronchoscopic 
results. 
 ‘p’ values were obtained using the Fisher Exact test to look at differences in CXR  
 signs between PJP and TB, and using the Kruskal – Wallis test for CD4 count medians. 
 
Agreement kappa tests were used for inter-reader correlation of CXR variables  and  
diagnoses categorised as follows: 
 Very good agreement kappa 0, 8 – 1 
 Good agreement kappa 0, 61 – 0, 8 
 Moderate agreement kappa 0, 41 – 0, 6 
 Fair agreement kappa 0, 21 – 0, 4 
 Poor agreement kappa < 0, 2 
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3 RESULTS 
Ninety two patients were included in the study. The mean age was 35,1 yrs ( range of 18-
62yr). There were 21 patients with bronchoscopically proven PJP and 25 with 
bronchoscopically proven TB. The mean age of PJP patients was 34,4yrs and that of the 
TB patients was 33,4 yrs. Females comprised 58,1% of 92 patients and 52,3% of 21 
patients with PJP. 
3.1 Bronchoscopic diagnoses of 92 patients are summarised in table 3.1         
Table 3.1: Diagnoses at bronchoscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 *sometimes multiple  
Diagnosis* Patients 
Pneumocystis pneumonia 21   (22,8%) 
Tuberculosis 25   (27,1%) 
Non Diagnostic 13  (14,1%) 
Lymphocytic interstitial pneumonia 9   (9,8%) 
Nonspecific interstitial pneumonia 8  (8,7%) 
Bacterial pneumonia 6  (6,5%) 
Normal bronchial tissue 5  (5,4%) 
Cytomegalovirus pneumonia 4  (4,3%) 
Candidiasis 3  (3,2%) 
Sarcoidosis 3   (3,2%) 
Aspergillosis 1  (1,08%) 
Bilharzia 1  (1,08%) 
Lymphoma 1  (1,08%) 
 
100 diagnoses in 92 patients 
(accounting for co-infections) 
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3.2 Co-infections 
1 patient had PJP and TB (counted twice under diagnoses)       
3 patients had both PJP and CMV 
1 patient had TB and Bilharzia and LIP 
1 patient had TB and Aspergillosis 
 
3.3 Proportion of PJP  
 The proportion of bronchoscopically proven PJP in 79 diagnostic samples (since 13  
samples were non diagnostic) was 26,6% 
 Co infection with PJP was 4/21 19%. 
 The proportion of bronchoscopically proven TB was 31,6 %. The remainder 
constituted 41, 8% of which LIP (11,3%) , NSIP (10,1%) and bacterial pneumonias 
(7,5%) were the larger groups. 
 Bacterial pneumonias were comprised of 3 klebsiella pneumonias, 2 staphylococcal 
pneumonias and 1 Haemophilus influenzae pneumonia 
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3.4 CD4 counts 
54 patients out of 92 patients had CD4 counts available.   
10 out of 21 PJP patients had CD4 counts available    
18 out of 24 TB patients had CD4 counts available. 
The available CD4 counts of the overall group, PJP subgroup and TB subgroup are 
summarised in Table 3.2. 
 
Table 3.2 CD4 counts in the total sample and according to subgroups PJP and TB 
  All patients PJP TB 
CD4 counts mean 153,7 (SD=188,5) 73,7  (SD=150,7) 204,6 (SD=193,7) 
Median (range) 101 (4 – 890) 13 (4 – 481) 125,5 ( 4 - 690) 
 
Mean CD4 count of the PJP group was the lowest (73,7 cells/mm
3
). A significant 
difference of median CD4 counts between the PJP and TB and other patients groups exists 
(p = 0, 0089) with the PJP median (13 cells/ mm
3 
)
  
being the lowest. In all three groups the 
median CD4 counts were < 150. 
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3.5 Sensitivity and specificity of CXR diagnosis vs bronchoscopy 
Reader 1 and Reader 2 had both an overall diagnostic sensitivity For PJP of 33% and a 
specificity 100%. Reader 1 and Reader 2 had the same sensitivites and specificities for the 
diagnosis of PJP, however , the true positive diagnosed on CXR  differed between Reader 
1 and Reader 2. These results are summarised in tables 3.3 and 3.4 below. 
 
Table 3.3 Reader 1 CXR diagnosis versus bronchoscopic diagnosis for PJP 
 
Bronchoscopy result 
Positive Negative 
CXR diagnosis 
Reader 1 
Positive 7 0 
Negative 14 71 
 
 
Table 3.4 Reader 2 CXR diagnosis versus bronchoscopic diagnosis for PJP 
 
Bronchoscopy result 
Positive Negative 
CXR diagnosis 
Reader 2 
Positive 7 0 
Negative 14 71 
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Reader 1 had a Sensitivity of 69% and Specificity of 55% for the CXR diagnosis of TB. 
Reader 2 had a Sensitivity 70% and a Specificity 62% for the CXR diagnosis of TB. These 
results are summarised in tables 3.5 and 3.6 below. 
 
Table 3.5 Reader 1 CXR diagnosis versus bronchoscopic diagnosis for TB 
 
 
Bronchoscopy result 
Positive Negative 
CXR diagnosis 
Reader 1 
Positive 18 30 
Negative 8 36 
 
Table 3.6 Reader 2 CXR diagnosis versus bronchoscopic diagnosis for TB 
 
 
Bronchoscopy result 
Positive Negative 
CXR diagnosis 
Reader 2 
Positive 19 25 
Negative 8 40 
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3.6 CXR features and patterns of PJP and TB 
The frequency of the following CXR variables was similar for PJP and TB: 
Bilateral, multilobar and diffuse disease, bronchopneumonia , nodules and cavitation.  
Cavitation was seen in 20% of 21 PJP cases and 20% - 52% of 25 TB cases, 
bronchopneumonia in 40- 60% of PJP and TB cases; nodules, diffuse, bilateral and 
multilobar disease were seen in over 70% of PJP cases and in 40 – 60% of TB cases.  
 
The frequency of the following CXR variables differed between PJP and TB: 
Effusions were absent in all PJP cases and were present in up to 20% of TB cases. 
Coarse reticulation was seen mainly in PJP (3 – 9 cases) and in 1 case of TB. 
Lymphadenopathy was rarely reported in PJP (no cases by reader 1 and 2 cases by reader 
2) and is reported in 5 – 8 of TB cases. 
 Lobar, focal, unilobar and unilateral variables are variables seen with greater frequency in 
TB. 
 
The above findings are detailed in table 3.7 and figures 3.1 to 3.5 below. 
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                  Table 3.7 CXR variables of PJP patients and TB patients for both readers. 
              
 
        CXR 
    Variables 
  PJP 
Reader 1 
    PJP 
Reader  2 
 
     TB 
Reader 1 
      TB 
Reader  2 
Bilateral 19 19 12 10 
Unilateral 2 2 11 13 
Multilobar 19 16 15 12 
Unilobar 2 2 8 11 
Diffuse 19 18 12 16 
Focal 1 1 2 4 
Bronchopneumonia 13 9 15 10 
Lobar 0 5 4 8 
Nodules 15 3 10 7 
Fine 4 1 1 0 
Coarse 9 3 1 1 
Effusions 0 0 4 5 
Cavitation 5 4 6 13 
Lymphadenopathy 0 2 5 8 
Pneumothorax 2 0 1 1 
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Figure 3.1 CXR features of bronchoscopically proven PJP for both readers  
Figure 3.1 shows the most common radiological features of PJP are bilateral, multilobar 
and diffuse patterns , which are also further detailed by bronchopneumonic consolidation, 
nodules, coarse reticulation and cavities (in a smaller percentages). Smaller numbers are 
reported with fine reticular patterns. There is absence of effusions in all 21 CXR’s. Two 
cases only (reported by one reader) had lymphadenopathy. Small numbers have 
pneumothorax.  
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Figure 3.2 Frequencies of ‘typical’ CXR signs of PJP 
Frequencies of ‘typical’ CXR signs of PJP according to typical patterns described by Waite 
et al and Webb et al (4,26). 
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Figure 3.3 Frequency of atypical radiological signs of PJP 
Frequency of ‘atypical’ radiological signs of PJP according to Waite et al and Webb et al 
(4, 26). 
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Figure 3.4 Comparison of CXR features of bronchoscopically proven PJP and TB for 
reader 1  
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Figure 3.5 Comparison of CXR features of bronchoscopically proven PJP and TB 
for reader 2. 
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3.7 Statistical differences of radiological variables between PJP and TB  
 
Reader 1 comparison PJP with TB                    Reader 2 comparison PJP with TB 
Unilateral vs Bilateral disease    p = 0.014            Unilateral vs Bilateral disease   p =0.003 
Unilobar vs Multilobar disease   p = 0.27              Unilobar vs Multilobar  disease  p = 0,03 
Focal vs Diffuse disease             p= 0.55                Focal vs Diffuse disease          p = 0.34 
Lobar vs Bronchopneumonic     p= 0.13                Lobar vs Bronchopneumonic     p = 0.89 
Fine vs Coarse Reticulation       p= 1.00               Fine vs Coarse reticulation        p = 1, 00 
 
‘p’ values of significant difference were present for Unilateral vs Bilateral disease in TB 
vs PJP in both readers, and for Unilobar vs multilobar in TB vs PJP  for reader 2. 
  
 48 
 
3.8 Inter Reader Agreement Test 
 
No CXR variables were agreed upon in the range of ‘very good’. 
 
There was ‘good agreement’ for the presence of effusions (kappa 0,68) and location of 
unilateral versus bilateral (kappa 0,63). 
 
There was ‘moderate agreement’ for unilobar versus multilobar distribution ( kappa 0,56) 
cavitation (kappa 0,53), nodules (kappa 0,43) and inter-reader diagnosis ( kappa 0,40) 
 
‘Fair’ agreement only was found between the variables of consolidation (kappa 0,35) 
reticulation (kappa 0,29) and description of focal versus diffuse disease (kappa 0,21). 
 
There was ‘poor’ agreement between readers for lymphadenopathy,  
 
‘No agreement’ took place between readers for cardiomegaly, bullous formation, 
pulmonary arterial hypertension and pneumothorax, as there were not enough patients 
reported with these variables. 
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4 DISCUSSION 
Proportion of PJP 
It is important to keep in mind that the sample population in this paper is a group of HIV 
patients not on ARV therapy, who had an indeterminate clinical and radiological diagnosis 
which led to bronchoscopy. The proportion that has been determined therefore does not 
represent the HIV population of the clinic, city or country. The proportion of 26.6% of PJP 
in our study, contrasts with the low prevalence reported in the early 1990’s in Africa (up to 
11%) (2, 29), but compares well with more recent reports from Zimbabwe (33%) in 1995 
(31), Ethiopia (30, 3%) in 2003(30), and 37,2% from Kenya in the same year (33) . In 1999 
Mahomed et al reported a PJP prevalence of 27% in HIV patients undergoing 
bronchoscopy in South Africa (36) which correlates well with our bronchoscopic findings. 
Co-infections affecting HIV infected patients confound diagnosis and classification of 
patients in research studies and range from 3.1% – 70% % (29, 30). Three of our patients 
with PJP had co-infection with CMV and 1 had co-infection with TB (19%). 
 
Level of immune suppression based on CD4 count 
Only 59% of our sample population and just under 50% of our PJP group had available 
CD4 counts. The mean overall CD4 count was 153 cells /mm
3 
(median 100) and that the 
PJP group had mean CD4 which was much lower at 73 cells / mm
3
 (median 13; p=0,0089). 
A study undertaken in South Africa in 2001 highlighted the non-specificity of chest 
radiographs in HIV infected patients with low CD4 counts and the difficulty in 
differentiating the different types of infection on chest radiographs. It is reported that as 
CD4 counts drop below 200 cells / mm
3
, the non-specificity of chest radiographs increases 
(23). This forms the basis for our study sample and it probably also contributes to the low 
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prevalence rates of PJP reported in Africa when bronchoscopic diagnosis was not 
employed.  
 
Diagnosis of PJP 
Our readers demonstrated excellent specificity for the overall diagnosis of PJP (100%) but 
a low sensitivity (33%) as opposed to the diagnosis of TB (sensitivity 70%). This suggests 
that when a diagnostic decision is made based on positive CXR features, unless the 
findings are very suggestive of PJP, a diagnosis of TB is made instead. This may be due to 
increased awareness, a high index of suspicion and probably better training regarding the 
diagnostic features of TB. The observation of a lower specificity for the overall diagnosis 
of TB on CXR (55% and 62%) confirms that the diagnosis of TB is overcalled to a greater 
degree than PJP, and that other diagnoses, such as PJP, are probably lost and not 
considered in the differential diagnosis. This is especially likely to occur during an era of 
HIV where 50% of TB cases are known to be smear negative (37).That is, patients with 
negative sputa results may be diagnosed with pulmonary TB in cases where bronchoscopy 
would yield a different diagnosis. New sputum nucleic acid amplification testing is 
emerging which will more accurately identify those patients with TB (98% of patients with 
smear- positive and culture- positive disease) and will include identification of greater than 
70% of patients with smear-negative and culture positive disease (37). 
 
CXR Findings 
A clear radiographic profile of PJP is evident from our results. PJP usually demonstrates 
bilateral, multilobar or diffuse disease. Coarse reticulation was far more common than the 
typical description of a fine reticular lacework pattern (seen in only 4 of our patients) 
reported in the literature. Bronchopneumonic and nodular patterns as well as cavitation, 
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were not typical CXR features of PJP and these overlapped with the CXR features reported 
in TB. This in part explains the low sensitivity of overall diagnosis of PJP. Importantly, 
differentiating it from TB, are the lack of effusions and lack of lymphadenopathy. 
Significantly, the statistical analysis identify unilateral and unilobar disease as indicators of 
TB rather than PJP on CXR. 
 
In summary and in practice, for HIV patients with low CD4 counts the following 
radiographic configuration can indicate the possibility of PJP on CXR: 
 Bilateral disease 
 Multifocal disease 
 Coarse reticular patterns 
 Bronchopneumonic consolidation 
 No effusions  
 No lymphadenopathy 
 
The following CXR signs are more likely to indicate TB : 
 Unilateral disease 
 Unilobar disease 
 Focal consolidation 
 Effusions 
 Lymphadenopathy 
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Inter-observer variability 
Observers showed a good agreement (Kappa 0.63 and 0.68 respectively) for determining 
bilateral vs unilateral disease and the presence or absence of effusions, moderate 
agreement for uni vs multi-lobar disease (Kappa 0.56) and only fair agreement on the 
presence of bronchopneumonic consolidation (Kappa 0.35) and reticulation (Kapppa 0.29). 
There was poor agreement (Kapppa 0.1) for the presence of lymphadenopathy. This 
suggests that reliable differentiators of PJP from TB are the presence of bilateral, 
multilobar disease and lack of effusions.  
 
Limitations and further studies The low patient numbers and the highly selected 
population are limitations of this study. The analysis was retrospective and as a result, 
incomplete CD4 counts were available. Complete CD4 count data together with acquiring 
a larger sample number of PJP patients could be done in a prospective study. Thirteen 
bronchoscopy results were non diagnostic and these may have included missed true 
positive or true negative results with regards to the diagnosis of both Pneumocystis 
pneumonia and TB. This is considered a limitation of the sensitivity and specificity results 
for both Pneumocystis pneumonia and TB in this study. Results may not be extrapolated to 
patients on ARV’s and of interest would be a study examining the spectrum of pulmonary 
diseases in these patients. 
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5 CONCLUSION 
PJP makes up more than one quarter of indeterminate CXR and clinical diagnoses in HIV 
infected patients. Low CD4 counts (< 200 cells / mm
3
) are associated with indeterminate 
diagnoses. Radiologists appear to be able to make a confident diagnosis in a proportion of 
these patients but sensitivity of diagnosis on radiographs is low, despite the increased 
clinical awareness of PJP in HIV positive patients. This study shows that in patients with 
low CD4 levels who have bilateral multifocal disease with reticular or bronchopneumonic 
patterns, and no effusions or lymphadenopathy, a diagnosis of PJP should be considered at 
least as equally important as a diagnosis of TB or other infections based on likelihood.   
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